Moderate Psoriasis Drug Pipeline Analysis Report 2025

Psoriasis is a chronic autoimmune condition that primarily affects the skin, causing red, scaly patches. It is estimated that around 2-3% of the global population, or over 125 million people, suffer from some form of psoriasis. The condition ranges from mild to severe, with moderate psoriasis being particularly prevalent. Current treatments, such as topical corticosteroids, biologics, and phototherapy, often fail to provide long-lasting relief, creating a high unmet clinical need for better therapies. As targeted therapies and precision medicine gain more focus, the development of innovative drugs, especially biologics, is expected to drive significant growth in the moderate psoriasis pipeline in the coming years, offering hope for more effective treatments.

Report Coverage

The Moderate Psoriasis Drug Pipeline Insight Report by the publisher gives comprehensive insights into moderate psoriasis therapeutics currently undergoing clinical trials. It covers various aspects related to the details of each of these drugs under development for moderate psoriasis. The moderate psoriasis report assessment includes the analysis of over 100 pipeline drugs and 50+ companies. The moderate psoriasis pipeline landscape will include an analysis based on efficacy and safety measure outcomes published for the trials, including their adverse effects on patients suffering from the condition, and alignment with moderate psoriasis treatment guidelines to ensure optimal care practices.

The assessment part will include a detailed analysis of each drug, drug class, clinical studies, phase type, drug type, route of administration, and ongoing product development activities related to moderate psoriasis.

Moderate Psoriasis Drug Pipeline Outlook

Moderate psoriasis is a chronic autoimmune skin disorder characterized by inflamed, red, and scaly plaques covering 3-10% of the body. It occurs when an overactive immune system accelerates skin cell turnover, leading to excessive buildup. Genetic predisposition, environmental triggers, and immune dysfunction contribute to its development. Stress, infections, and certain medications can worsen symptoms, impacting patients' quality of life.

Moderate psoriasis treatment includes topical therapies like corticosteroids and vitamin D analogs, phototherapy, and systemic treatments. Biologic drugs targeting immune pathways, such as IL-17 and IL-23 inhibitors, offer advanced options. Traditional systemic therapies like methotrexate and cyclosporine are also prescribed. Personalized treatment plans, integrating lifestyle modifications and emerging therapies, continue to improve patient outcomes.

Moderate Psoriasis Epidemiology

Psoriasis affects 2-3% of the global population, with over 125 million cases worldwide. In the United States, its prevalence is 1.4%, while the United Kingdom has prevalence rates between 0.7% and 2.6%. Japan has over 500,000 cases at a 0.34% prevalence, which is expected to rise. In India, prevalence ranges from 0.44% to 2.8%. Advancements in biologics and targeted therapies are driving drug pipeline growth.

Moderate Psoriasis Drug Pipeline Therapeutic Assessment

This section of the report covers the analysis of moderate psoriasis drug candidates based on several segmentations, including:

By Phase

• Late-Stage Products (Phase 3 and Phase 4)
• Mid-Stage Products (Phase 2)
• Early-Stage Products (Phase I)
• Preclinical and Discovery Stage Products

By Drug Class

• Small Molecules
• Monoclonal Antibodies
• Gene Therapies
• Topical Therapies

By Route of Administration

• Oral
• Parenteral
• Others

Moderate Psoriasis Pipeline Assessment Segmentation, By Phases

The report covers phase I, phase II, phase III, phase IV, and early-phase drugs. The coverage includes an in-depth analysis of each drug across these phases. According to analysis, phase III covers a major share of the total moderate psoriasis clinical trials.

Moderate Psoriasis - Pipeline Assessment Segmentation, By Drug Classes

The drug molecule categories covered under the moderate psoriasis pipeline analysis include small molecules, monoclonal antibodies, gene therapies, and topical therapies. The phase III report provides a comparative analysis of the drug classes for each drug in various phases of clinical trials for phase III.

Moderate Psoriasis Clinical Trials Therapeutic Assessment - Competitive Dynamics

The report for the moderate psoriasis drug pipeline covers the profile of key companies involved in clinical trials and their drugs under development. It provides a detailed moderate psoriasis therapeutic assessment, analyzing the competitive dynamics of the clinical trial landscape. Below is the list of a few players involved in moderate psoriasis clinical trials:

• AbbVie
• Janssen Research & Development, LLC
• Suzhou Suncadia Biopharmaceuticals Co., Ltd.
• Sun Pharmaceutical Industries Limited
• SFA Therapeutics
• Beijing InnoCare Pharma Tech Co., Ltd.
• UCB Biopharma SRL
• Chia Tai Tianqing Pharmaceutical Group Co., Ltd.
• Amgen
• Eli Lilly and Company
• InventisBio Co., Ltd.
• Bristol-Myers Squibb

Moderate Psoriasis Emerging Drugs Profile

This section covers the detailed analysis of each drug under multiple phases, including phase I, phase II, phase III, phase IV, and emerging drugs for moderate psoriasis. It includes product description, trial ID, study type, drug class, mode of administration, and recruitment status of moderate psoriasis drug candidates.

Drug: Vunakizumab (IL-17

A inhibitor)
A Phase IV study sponsored by Suzhou Suncadia Biopharmaceuticals Co., Ltd. aims to evaluate the efficacy and safety of Vunakizumab in adults with moderate-to-severe plaque psoriasis who have transitioned from other biologics. The study will also assess patient satisfaction and reported outcomes. The study is expected to enroll nearly 1,564 participants and is projected to be completed by February 2028.

Drug: Guselkumab

Janssen Research & Development is sponsoring a Phase IIIb study, that evaluates the efficacy of Guselkumab versus placebo in treating low body surface area moderate plaque psoriasis with special site involvement. The study aims to assess safety and effectiveness. It is expected to conclude by April 2025, with approximately 338 participants estimated to enroll.

Drug: Bimekizumab

The Phase II study, sponsored by UCB Biopharma SRL, evaluates the pharmacokinetics, safety, and efficacy of two doses of Bimekizumab in adolescents with moderate to severe plaque psoriasis. The study will involve about 41 participants and aims to assess subcutaneous administration. It is expected to be completed by March 2025.

Reasons To Buy This Report

The Moderate Psoriasis Drug Pipeline Insight Report provides a strategic overview of the latest and future landscape of treatments for moderate psoriasis. It provides necessary information for making informed investment decisions along with research, development, and strategic planning efforts. The stakeholders will benefit from the essential insights into moderate psoriasis collaborations, regulatory environments, and potential growth opportunities.

Key Questions Answered in the Moderate Psoriasis - Pipeline Insight Report

• Which companies/institutions are leading the moderate psoriasis drug development?
• What is the efficacy and safety profile of moderate psoriasis pipeline drugs?
• Which company is leading the moderate psoriasis pipeline development activities?
• What is the current moderate psoriasis commercial assessment?
• What are the opportunities and challenges present in the moderate psoriasis drug pipeline landscape?
• What is the efficacy and safety profile of moderate psoriasis pipeline drugs?
• Which company is conducting major trials for moderate psoriasis drugs?
• Which companies/institutions are involved in moderate psoriasis collaborations aimed at providing enhanced therapeutic alternatives for patients?
• What are the geographies covered for clinical trials in moderate psoriasis?

This product will be delivered within 3-5 business days.